WHO ICTRP trial
The efficacy and safety of different dosage of amoxicillin-voronazan dual…
ChiCTR2200064874 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200064874 |
|---|---|
| Public title | The efficacy and safety of different dosage of amoxicillin-voronazan dual therapy for 14 days in Helicobacter pylori eradication: A prospective, randomized, open clinical trial |
| Scientific title | The efficacy and safety of different dosage of amoxicillin-voronazan dual therapy for 14 days in Helicobacter pylori eradication: A prospective, randomized, open clinical trial |
| Primary sponsor | The First Affiliated Hospital of Nanchang University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Helicobacter pylori infection |
| Interventions | Group 1:amoxicillin (1g bid) and voronazan (20mg bid) for 14 days ;Group 2:amoxicillin (1g tid) and voronazan (20mg bid) for 14 days |
| Registration date | Oct 20, 2022 |
| Target size | Group 1:55;Group 2:55 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: